These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 23983935)

  • 1. Tolerability of initiation doses of once-monthly paliperidone palmitate in patients with recently diagnosed schizophrenia in an acute treatment trial.
    Bossie CA; Fu DJ; Sliwa JK; Ma YW; Alphs L
    Ther Adv Psychopharmacol; 2011 Aug; 1(4):111-24. PubMed ID: 23983935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Onset of efficacy and tolerability following the initiation dosing of long-acting paliperidone palmitate: post-hoc analyses of a randomized, double-blind clinical trial.
    Bossie CA; Sliwa JK; Ma YW; Fu DJ; Alphs L
    BMC Psychiatry; 2011 May; 11():79. PubMed ID: 21569242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paliperidone palmitate versus oral risperidone and risperidone long-acting injection in patients with recently diagnosed schizophrenia: a tolerability and efficacy comparison.
    Fu DJ; Bossie CA; Sliwa JK; Ma YW; Alphs L
    Int Clin Psychopharmacol; 2014 Jan; 29(1):45-55. PubMed ID: 24113628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophrenia.
    Sliwa JK; Bossie CA; Fu DJ; Turkoz I; Alphs L
    Neuropsychiatr Dis Treat; 2012; 8():375-85. PubMed ID: 22956873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paliperidone palmitate versus risperidone long-acting injection in markedly-to-severely ill schizophrenia subjects: onset of efficacy with recommended initiation regimens.
    Fu DJ; Bossie CA; Kern Sliwa J; Ma YW; Alphs L
    Clin Schizophr Relat Psychoses; 2014 Jul; 8(2):101-9, 109A. PubMed ID: 23446197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paliperidone palmitate for schizophrenia.
    Nussbaum AM; Stroup TS
    Cochrane Database Syst Rev; 2012 Jun; (6):CD008296. PubMed ID: 22696377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia.
    Pandina GJ; Lindenmayer JP; Lull J; Lim P; Gopal S; Herben V; Kusumakar V; Yuen E; Palumbo J
    J Clin Psychopharmacol; 2010 Jun; 30(3):235-44. PubMed ID: 20473057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Onset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trial.
    Alphs L; Bossie CA; Sliwa JK; Ma YW; Turner N
    Ann Gen Psychiatry; 2011 Apr; 10(1):12. PubMed ID: 21481243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of the 3-Month Formulation of Paliperidone Palmitate vs Placebo for Relapse Prevention of Schizophrenia: A Randomized Clinical Trial.
    Berwaerts J; Liu Y; Gopal S; Nuamah I; Xu H; Savitz A; Coppola D; Schotte A; Remmerie B; Maruta N; Hough DW
    JAMA Psychiatry; 2015 Aug; 72(8):830-9. PubMed ID: 25820612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dosing and switching strategies for paliperidone palmitate: based on population pharmacokinetic modelling and clinical trial data.
    Samtani MN; Gopal S; Gassmann-Mayer C; Alphs L; Palumbo JM
    CNS Drugs; 2011 Oct; 25(10):829-45. PubMed ID: 21936586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Practical guidance for dosing and switching paliperidone palmitate treatment in patients with schizophrenia.
    Gopal S; Gassmann-Mayer C; Palumbo J; Samtani MN; Shiwach R; Alphs L
    Curr Med Res Opin; 2010 Feb; 26(2):377-87. PubMed ID: 20001492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of acute paliperidone palmitate treatment in subjects with schizophrenia recently treated with oral risperidone.
    Sliwa JK; Bossie CA; Ma YW; Alphs L
    Schizophr Res; 2011 Oct; 132(1):28-34. PubMed ID: 21775106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study.
    Hough D; Gopal S; Vijapurkar U; Lim P; Morozova M; Eerdekens M
    Schizophr Res; 2010 Feb; 116(2-3):107-17. PubMed ID: 19959339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Profile of paliperidone palmitate once-monthly long-acting injectable in the management of schizophrenia: long-term safety, efficacy, and patient acceptability - a review.
    González-Rodríguez A; Catalán R; Penadés R; Garcia-Rizo C; Bioque M; Parellada E; Bernardo M
    Patient Prefer Adherence; 2015; 9():695-706. PubMed ID: 26082620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extended-release intramuscular paliperidone palmitate: a review of its use in the treatment of schizophrenia.
    Carter NJ
    Drugs; 2012 May; 72(8):1137-60. PubMed ID: 22571444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Post-hoc comparison of paliperidone palmitate to oral risperidone during initiation of long-acting risperidone injection in patients with acute schizophrenia.
    Gopal S; Pandina G; Lane R; Nuamah I; Remmerie B; Coppola D; Hough D
    Innov Clin Neurosci; 2011 Aug; 8(8):26-33. PubMed ID: 21922067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study.
    Gopal S; Hough DW; Xu H; Lull JM; Gassmann-Mayer C; Remmerie BM; Eerdekens MH; Brown DW
    Int Clin Psychopharmacol; 2010 Sep; 25(5):247-56. PubMed ID: 20389255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paliperidone Palmitate 3-Monthly Versus 1-Monthly Injectable in Patients With Schizophrenia With or Without Prior Exposure to Oral Risperidone or Paliperidone: A Post Hoc, Subgroup Analysis.
    Mathews M; Pei H; Savitz A; Nuamah I; Hough D; Alphs L; Gopal S
    Clin Drug Investig; 2018 Aug; 38(8):695-702. PubMed ID: 29882073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia.
    Hough D; Lindenmayer JP; Gopal S; Melkote R; Lim P; Herben V; Yuen E; Eerdekens M
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Aug; 33(6):1022-31. PubMed ID: 19481579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia.
    Coppola D; Liu Y; Gopal S; Remmerie B; Samtani MN; Hough DW; Nuamah I; Sulaiman A; Pandina G
    BMC Psychiatry; 2012 Mar; 12():26. PubMed ID: 22455454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.